Hyperphosphatemic Tumoral Calcinosis With Pemigatinib Use

Hyperphosphatemic Tumoral Calcinosis With Pemigatinib Use

Background/Objective: Pemigatinib, a fibroblast growth factor receptor (FGFR) 1-3 inhibitor, is a novel therapeutic approach for treating cholangiocarcinoma when an FGFR fusion or gene rearrangement is identified. Although the most reported side effect of pemigatinib is hyperphosphatemia, tumoral ca...

Full description

Bibliographic Details
Main Authors: Akshan Puar, MBBS, Diane Donegan, MD, Paul Helft, MD, Matthew Kuhar, MD, Jonathan Webster, MD, Megana Rao, BS, Michael Econs, MD
Format: Article
Language:English
Published: Elsevier 2022-09-01
Series:AACE Clinical Case Reports
Subjects:
hyperphosphatemia
fibroblast growth factor receptor
fibroblast growth factor 23
calcification
Online Access:http://www.sciencedirect.com/science/article/pii/S2376060522000475

Internet

http://www.sciencedirect.com/science/article/pii/S2376060522000475

Similar Items